Search - tctmd.com

Displaying 41 - 60 of 2764

Sort: Relevancy | Date

Presentation TCT 2025

Placebo-Controlled Interventional Trials: A Sham No More

Presenter: Rasha Al-Lamee

October 27, 2025

Presentation TCT 2025

Spoiler Alert: Crossovers (Treatment Switches) can Negate the Trial Efficacy: Insights from The Ischemia Trial

Presenter: John Gregson

October 27, 2025

Presentation TCT 2025

The Core of Clinical Event Adjudication: Where is CEC Now and Where Do They Go Next?

Presenter: Marc P. Bonaca

October 27, 2025

Presentation TCT 2025

TCT 447: Invisible Hearts: The Underrepresentation of Women in Cardiovascular Clinical Trials

Presenter: Pablo Juan Salvadores

October 27, 2025

News Conference News TCT 2025

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

Yael L. Maxwell

October 26, 2025

News Conference News TCT 2025

Left Distal Radial Access Doesn’t Reduce Radiation for Operators: DOSE

Caitlin E. Cox

October 25, 2025

News Features

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

Todd Neale

October 22, 2025

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Getting Ready for a Heart Failure Polypill, Well Before the Data Are In

Todd Neale

October 16, 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

News Conference News HFSA 2025

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

Yael L. Maxwell

October 01, 2025

News Conference News HFSA 2025

Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74

Yael L. Maxwell

September 30, 2025

News Daily News

Lactate Clearance May Act as ‘Early Warning Sign’ in Cardiogenic Shock

L.A. McKeown

September 25, 2025

News Daily News

European Experts Provide Advice on Managing CV Effects of COVID-19

Todd Neale

September 19, 2025

News Features

‘Buzz and Discussion’ Driving Return to In-Person Cardiology Meetings

Michael O'Riordan

September 17, 2025

News Industry News

Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz’s Safety and Efficacy in Elderly Heart Attack Patients

September 15, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

DanGer Shock: Impella Tied to Better Survival Even 10 Years Later

Caitlin E. Cox

September 08, 2025

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

L.A. McKeown

September 05, 2025

Advertisement

Placebo-Controlled Interventional Trials: A Sham No More

Spoiler Alert: Crossovers (Treatment Switches) can Negate the Trial Efficacy: Insights from The Ischemia Trial

The Core of Clinical Event Adjudication: Where is CEC Now and Where Do They Go Next?

TCT 447: Invisible Hearts: The Underrepresentation of Women in Cardiovascular Clinical Trials

More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain

Left Distal Radial Access Doesn’t Reduce Radiation for Operators: DOSE

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Getting Ready for a Heart Failure Polypill, Well Before the Data Are In

What’s Going to Be Hot at TCT 2025

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Acoramidis Halves Cumulative CV Events Within 6 Months: ATTRibute-CM

Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74

Lactate Clearance May Act as ‘Early Warning Sign’ in Cardiogenic Shock

European Experts Provide Advice on Managing CV Effects of COVID-19

‘Buzz and Discussion’ Driving Return to In-Person Cardiology Meetings

Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz’s Safety and Efficacy in Elderly Heart Attack Patients

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

DanGer Shock: Impella Tied to Better Survival Even 10 Years Later

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content